2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2118

Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Abstract Number: 734

Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Abstract Number: 878

Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
Abstract Number: 2791

Lung Cancer in SLE
Abstract Number: 2976

Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice
Abstract Number: 705

Lupus Chest Pain in the Emergency Department: a Common Diagnostic Dilemma
Abstract Number: 2989

Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
Abstract Number: 694

Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics
Abstract Number: 1311

Lupus Nephritis in Mexican Children
Abstract Number: 1662

Lupus Nephritis Patients Who Stopped Maintenance Immunosuppressive Therapy without Relapse
Abstract Number: 1655

Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies
Abstract Number: 690

Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course – a Phenotypic Description
Abstract Number: 713

Lupuspro Is Responsive to Changes in Disease Activity over Time
Abstract Number: 1

Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome
Abstract Number: 2299

M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].